1 **Disease-specific plasma protein profiles in patients with fever after traveling to**
2 **tropical areas**
3

4 Klara Sondén[1,2*], Victor Yman[1,3], Zaynab Mousavian[1,2,4], Sina Angenendt[1], Fariba
5 Foroogh[1], Ellen von Horn[1], Maximilian Julius Lautenbach[1,2,4], Johan Grunewald[4,5],
6 Anna Färnert[1,2,4], Christopher Sundling[1,2,4*]
7
[1] Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet,
Stockholm, Sweden
[2] Department of Infectious Diseases, Karolinska University Hospital, Stockholm
Sweden
[3] Department of Infectious Diseases, Stockholm South Hospital, Stockholm, Sweden
[4] Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
[5] Respiratory Medicine Unit, Department of Medicine, Solna, Karolinska Institutet and
Karolinska University Hospital Solna, Stockholm, Sweden
16
17 **Running title**: Inflammatory proteins as biomarkers of disease type
18
19 **Corresponding author**: Klara Sondén, klara.sonden@ki.se or Christopher Sundling,
20 christopher.sundling@ki.se
21

Abstract

Objectives

Fever is common among individuals seeking healthcare after traveling to tropical regions. Despite the association with potentially severe disease, the etiology is often not determined. Cytokines are soluble mediators dynamically regulated in the response to infection. Measuring cytokines in the blood can therefore be informative to understanding the host-response to infection and can potentially indicate the type of pathogen that causes the disease.

Method

In this study, we measured 49 host-response proteins in the plasma of 124 patients with fever after travel to tropical or subtropical regions. The patients had confirmed diagnosis of either *P. falciparum* malaria, dengue virus, influenza virus, bacterial respiratory tract infection, or culture-confirmed bacterial gastroenteritis, representing the most common disease etiologies. We used multivariate and machine learning methods to assess host-response protein profiles between the different disease groups and healthy control subjects with the aim to identify disease-specific protein signatures.

Results

The host-response varied between disease groups and combinations of cytokines and other proteins could accurately distinguish infected patients from healthy controls, and from each other. Malaria displayed the most unique protein signature, indicating a strong immunoregulatory response with high levels of IL10, sTNFRI and II, and sCD25 but low levels of sCD40L. In contrast, bacterial gastroenteritis had high levels of sCD40L, APRIL, and IFN-γ, while dengue was the only infection with elevated IFNα2.

Conclusions

These results suggest that characterization of the inflammatory profile of individuals with fever can help to identify disease-specific host-responses, which in turn can be used to guide further diagnostic strategies.

Key words: Cytokines, fever, travel medicine, dengue, malaria, influenza, pneumonia, gastroenteritis, diagnostics

Introduction

Fever is a common symptom of individuals seeking healthcare after returning from travel to tropical areas[1]. In a previous study in Sweden, most of these cases were shown to be due to gastroenteritis, malaria, influenza, and dengue virus, but >40% remained with unknown etiology even after healthcare contact[2]. Upon further serological analysis of those with unknown etiology, approximately 9% were found to have a likely influenza virus infection, 4% dengue virus infection, and another 4% with Rickettsial infection[2]. This highlights the difficulties in travel medicine as the number of pathogens that need to be considered is numerous, and patients with various diagnoses often present with overlapping clinical symptoms[3–6]. Pathogens that can give rise to severe disease are important to detect at an early stage, while at the same time, unnecessary antibiotic usage should be avoided[7]. Learning more about how immune responses differ between infections with similar clinical presentations could potentially be informative in developing biomarker signatures for disease identification and for a better understanding of host-pathogen interaction and protective immunity.

During infection, a wide range of inflammatory proteins are up- or downregulated in the host's response to the pathogen. Depending on the infecting pathogen, different types of immune responses are important for efficient control[8]. These inflammatory responses tend to be short-lived and self-regulatory as the pathogen is controlled. However, in some instances, the inflammatory response becomes dysregulated leading to severe disease manifestations[9–11]. Measuring inflammatory proteins in the blood can therefore help to understand the host inflammatory response to infection, and predict disease severity[12–17] or disease etiology[18]. Different infections may induce overlapping inflammatory protein profiles and studying a single infection in isolation will make it difficult to understand the pathogen-specificity of the responses and limit the possibility to discern how patterns differ between infections. Recently developed experimental and bioinformatics methods allow for comprehensive analysis of cytokine profiles useful for mapping immunological events as well as for identification of clinically relevant markers of disease and its severity[18–22].

This study provides a comprehensive mapping of inflammatory proteins in the plasma of individuals with a known etiology of infection who presented with fever after travel to tropical or sub-tropical areas. By comparing the inflammatory profile

93 between the different disease groups, we could identify patterns associated with the
94 respective etiologies. These patterns provide insights regarding the pathogen
95 specificity of the host inflammatory response to infection and could potentially be
96 further explored as biomarkers for clinical practice in the future.

Methods

Study inclusion

Patients with a history of travel were invited to participate when seeking care at
the Emergency Department at Karolinska University Hospital, Stockholm, Sweden.
Inclusion criteria were: i) Travel within the past 2 months to a tropical (defined as
between latitude 0°-±23.5°) or sub-tropical area (defined as between latitude ±23.5°-
±40°), ii) age ≥18 years, and iii) documented body temperature >38°C at the hospital
or self-reported fever within the previous 2 days. Blood samples for serum and EDTA
plasma isolation were collected from all individuals and aliquots were frozen for later
analysis. Demographic and clinical data, including microbiological diagnosis after
routine clinical investigation, were extracted from medical records and a
questionnaire filled in by patients. Five groups of diagnoses were selected for further
study: 1) Malaria caused by *Plasmodium falciparum* as defined by microscopy and
qPCR, 2) Dengue diagnosed by a positive result in qPCR for dengue virus, 3)
Gastroenteritis with fecal culture positive for enteropathogenic bacteria, 4) Influenza
diagnosed by positive qPCR for influenza virus in the nasopharyngeal swab, and 5)
Respiratory tract bacterial infections defined as nasopharyngeal culture positive
together with chest x-ray with infiltrate or sputum culture positive for a respiratory
pathogen together with signs or symptoms indicative of bronchitis or pneumonia. In
addition, 13 healthy adult individuals without a current history of travel were sampled
as controls. The study was approved by the Swedish Ethical Review Authority
(2016/2512-31/2). Study participants were provided with written and oral information
and written consent was obtained.

In addition to the study inclusion for all tropical fevers, patients with
symptomatic malaria had since 2011 been included in a prospective malaria
immunology cohort previously investigated for longitudinal parasite prevalence,
parasite-specific antibodies, and B cell responses[23–25]. These individuals were
enrolled at the Karolinska University Hospital after confirmed microscopy for *P.*

falciparum and providing informed consent. The study was approved by the Swedish
Ethical Review Authority (2006/893-31/4 with addendums 2018/2354-32 and 2019-
03436).

Multiplex cytokine measurements

Plasma aliquots were thawed at room temperature (RT) and cytokines and
chemokines were measured using the LEGENDplex™ pre-defined 13-plex panels
according to the manufacturer's instructions with some modifications. The panels
used were; cytokine panel 2, inflammation panel 2, proinflammatory chemokine
panel, and the B cell panel (all from Biolegend), measuring 49 unique inflammatory
markers in total (**Supplementary Table 1**).

Briefly, 12.5 µl plasma was mixed with 12.5 µl multiplex beads and diluted to 75
µl and incubated for 2h at RT in a plate shaker (700 rpm). The beads were then
washed and incubated with 12.5 µl biotin-conjugated marker-specific antibodies
diluted to 25 µl with phosphate buffered saline (PBS) for 45 min at RT in a plate
shaker (700 rpm). 12.5 µl PE-conjugated streptavidin was then diluted with PBS to 25
µl and added to each well without washing and incubated for 30 min at RT in a plate
shaker (700 rpm). The beads were then washed twice, and the fluorescent signal
was measured on a BD 4-laser Fortessa using the 488 nm laser (forward scatter vs
side scatter) to separate beads based on size and granularity and the 640 nm laser
(780/60 filter) to separate beads based on cytokine specificity. The 561 nm laser
(582/16) filter was then used to detect the amount of marker signal, translating to the
amount of cytokine. The median fluorescent signals were then exported, and the
concentration of each marker was determined for each sample based on interpolation
from sigmoidal dose-response curves established for each cytokine based on the
standards included with the kits.

Statistical analysis and machine learning
Differential expression analysis

Data management and statistical analysis were performed using R
programming language. All data on cytokine levels were log-transformed prior to
analysis. Spearman's rank correlation was used to construct correlation networks of
cytokine levels within each disease group. For the graphical display of correlation

networks, only correlations with absolute values of Spearman's rho > 0.7 were
included. Mann-Whitney-U tests were applied to evaluate differences in the median
cytokine levels between the different types of infections or healthy controls. All p-
values were adjusted for false discovery rate (FDR)[26]. FDR-adjusted *P*-values < 0.05
were considered significant.

Discriminant analysis of principal components

Discriminant analysis of principal components (DAPC) was used to examine the
multidimensional cytokine data (49 proteins) for specific cytokine profiles/signatures
associated with each infection type[27]. DAPC is a dimensionality reduction method
that identifies the vectors (linear discriminants) in multidimensional space which
provides maximum discrimination of groups while minimizing variation within groups.
DAPC first transforms the data into uncorrelated variables using principal component
analysis and then performs a discriminant analysis on the retained principal
components (PCs). The optimal number of PCs to retain for discriminant analysis
was determined by cross-validation to be 26. Prior to DAPC analysis, all log-
transformed values of cytokine levels were scaled and centered by dividing by the
median absolute deviation and by subtracting the median, respectively.

Feature selection and ROC analysis

The Boruta feature selection algorithm[28] based on binary classification was
applied to identify only plasma proteins that contribute significant information for
identifying each type of infections from the others and healthy controls. For each
infection type, random forest classifiers were then fitted to all the down selected
cytokines identified by the Boruta algorithm and the predictive performance was
evaluated using receiver operating characteristic (ROC) analysis with 5-fold cross-
validation. All data was divided into five parts and in each run, four parts of data were
used for model training and the remaining one was used for testing. To further reduce
the risk of over-fitting of the classification algorithms, a repeated k-fold cross-
validation with 10 repeats and 10 folds was applied for parameter tuning within the
model training process. Finally, all ROC plots obtained from five different runs of the
model were aggregated into one ROC plot to show the average performance of the
model. An imbalanced dataset can result in biased learning algorithms due to
differences in the number of individuals in each class. This bias can lead to overly

optimistic ROC results that may not be realistic. To address this issue, we also used

precision-recall curves to provide a more accurate representation of each model's

performance.

Results

Clinical characteristics

In total 520 patients were included in the study between February 2017 and February 2020. Samples from 75 individuals were selected as they presented the five most common etiologies within the cohort. The purpose was to investigate if these most common diagnoses were associated with unique patterns in their inflammatory responses that could potentially be used in identifying the causative agent of the infection. In addition, samples from 49 individuals were included from a separately collected malaria cohort. A total of 17 patients had dengue fever, 26 had gastroenteritis, 26 had influenza, 49 had *P. falciparum* malaria, and 6 had bacterial respiratory tract infections. In addition, 14 healthy individuals were sampled (**Table 1**). Patients with *P. falciparum* malaria were admitted to the hospital per routine (93.6% of patients) for treatment and observation. Hospital admission was lower in the other groups, with dengue (35.3%), gastroenteritis (38.5%), influenza (19.2%), and respiratory tract infection (66.7%). Among patients with nasal swabs positive for Influenza, 12 patients had Influenza A and 14 had Influenza B. Fecal cultures in the group with clinical gastroenteritis revealed growth of either *Salmonella spp.* (n=12) or *Campylobacter spp.* (n=14).

There was no significant difference in axillary temperature between the infections. They did however differ significantly in leukocyte and platelet counts and levels of C-reactive protein (**Supplementary Figure 1**). Patients with dengue and malaria had significantly lower leukocyte counts compared to bacterial gastroenteritis while dengue also had significantly lower counts compared to influenza and bacterial respiratory tract infection. Platelet counts were significantly lower in the malaria group compared to all other infections. CRP was significantly elevated in all infections except dengue fever which remained close to the reference values. There was no significant difference in CRP values between bacterial gastroenteritis, influenza, and bacterial respiratory tract infection, while malaria was significantly higher than influenza (**Supplementary Figure 1**).

231 **Table 1.** Clinical characteristics of patients included in the study (n=124)

	Dengue n=17	Bacterial gastroenteritis n=26	Influenza n=26	Malaria n=49	Bacterial respiratory tract infection n=6	Healthy controls N=14
Age, median (IQR)	37 (33-50)	36 (28-46)	37 (31-55)	38 (30-44)	57 (39-68)	30 (26-34)
Female sex, n (%)	6 (35.3)	12 (46.2)	15 (57.7)	9 (18.4)	4 (66.7)	10 (71.4%)
Admitted to hospital, n (%)	6 (35.3)	10 (38.5)	5 (19.2)	46 (93.9)	4 (66.7)	N/A
Leukocytes[†], ($\times 10^9$/L), median (range)	3.1 (2-7.4)	8.8 (4.2-18.9)	5.5 (3-20)	5 (1.9-35)	8.9 (6.9-11.3)	Not measured
Platelets[§], ($\times 10^9$/L), median (range)	157 (58-346)	205 (131-549)	194 (106-442)	85 (12-210)	233 (188-367)	Not measured
C-reactive protein[‡], (mg/L), median (range)	4 (1-62)	39 (0-274)	29 (2-277)	92 (6-294)	65 (33-223)	Not measured
Microbiological findings	Dengue virus qPCR positive n=17	Feces culture positive for Salmonella species: n=12 Campylobacter: n=14	Influenza qPCR nasal swab positive for Influenza A: n=12 Influenza B: n=14	Blood smear and qPCR. *P. falciparum* n=49. Mean parasitemia 1.7 % range (0.01-17)	Culture positive for *H. Influenzae* Sputum n=4 Nasopharyngeal swab n=2	N/A

232 [†]Normal range for Leucocytes 3.8–8.8 × 10^9/L
233 [§]Normal range for platelets 150-400 × 10^9/L
234 [‡]Normal range for C-reactive protein 0–3 mg/L
235

Different types of infection display unique profiles of inflammatory markers

We measured the levels of 49 different inflammatory proteins in the plasma

from the study participants and healthy controls (**Figure 1**). There was a substantial

variation in the levels of the proteins among individual donors (**Figure 1A**), however,

several disease-specific patterns could be observed (**Figure 1B**). For many of the

measured cytokines, levels were highly positively correlated across infections

(**Supplementary Figure 2**) as well as within specific infections (**Supplementary**

Figure 3).

Figure 1. Levels of inflammatory proteins in plasma in different types of infections. (**A**) Heatmap of normalized individual cytokine levels. Each column represents an individual and each row represents a cytokine. Columns are ordered based on disease etiology and rows are ordered using hierarchical clustering based on euclidean distance. (**B**) Heatmap of normalized group-wise median cytokine levels. Each column represents a disease etiology group while each row represents a cytokine.

We next compared the levels of the 49 inflammatory markers between each group and healthy controls using repeated Mann-Whitney-U tests, corrected for multiple testing, to assess if different disease etiologies were associated with up- or downregulation of specific proteins (**Figure 2A**). Out of the 49 proteins, 29 were significantly up- or downregulated between the different infections or healthy controls (**Figure 2A**). Compared to healthy controls, dengue patients had a significant increase in 14 out of the 49 measured proteins (logFC>1 and FDR p-value<0.05), while bacterial gastroenteritis led to a significant increase in 18 proteins, and bacterial respiratory tract infection of 3 proteins. Influenza had a significant increase of 12

proteins and the reduction of 1 protein whereas malaria led to significantly increased
levels of 17 proteins and reduced levels of 3 proteins. BAFF, IL6, IP10 (CXCL10),
ITAC (CXCL11), MCP1 (CCL2), MIG (CXCL9), MIP1β, PTX3, sCD25, and sST2
were increased in most infections, potentially indicating quite general markers of
febrile illness. There were, however, considerable differences in levels between the
groups for some of the markers, such as IP10, where all individuals with dengue had
levels above the limit of detection for the assay, and sCD25, which was higher in
especially malaria (**Figure 2B**).
Some proteins were primarily associated with specific pathogens, such as IFNγ
and APRIL which were significantly increased in bacterial gastroenteritis, and IFNα2
which was upregulated in dengue compared with bacterial gastroenteritis, malaria,
and healthy controls. IL10 levels were significantly elevated in influenza, dengue
infection, and malaria, with increasing amounts, while changes to IL18, CD40L,
sTNFRI, and TARC were largely specific for malaria. GMCSF levels were slightly
lower in influenza compared to healthy controls only (**Figure 2A**). In total, 20 out of
the 49 proteins did not differ significantly in any comparison between the different
diseases and healthy controls (**Supplementary Figure 4**).

Figure 2. Comparison of inflammatory proteins between disease groups. (*A*) *Log-transformed levels (pg/mL) of inflammation-associated proteins were compared between all groups and significant differences, as determined by the FDR-adjusted Mann-Whitney tests, are shown as dots where the size of the dot indicates the p-value and the color indicates a positive (red) or negative (blue) fold-change between the compared groups. (*B*) Log-transformed cytokine levels are shown for individual donors in each group. Box plots indicate median and interquartile range.*

Immune signatures associated with different disease groups

The inflammatory response to infection is complex and is likely affected by the type of pathogen, its virulence, and the anatomical location of the infection. To be able to assess the complexity of the inflammatory response and examine if different diseases were associated with different inflammatory patterns, we used discriminant analysis of principal components (DAPC) (**Figure 3 and Supplementary Figures 5 and 6**). This type of analysis enables us to focus on between-group variability while

minimizing within-group variability to identify key markers that segregate the groups
included in the analysis[27].

Discriminant function 1 (DF1) provided clear segregation between malaria and
the other diseases (**Figure 3A**). Differences in DF1 were largely driven by IL10 levels
but also influenced by several other proteins, especially IL6, CXCL12, CD40L,
sCD25, and sRAGE (**Figure 3B**). DF2 was instead important for segregating the
infected groups from the healthy controls and somewhat from each other. This was
largely driven by MIG, but also further influenced by sCD130, IFNα2, CCL11, and
IL2. DF3 provided a weaker separation primarily of bacterial gastroenteritis from
dengue. This was associated with e.g., IFNα2, as described before, but also TSLP,
IL6, MIG, and IL10.

Figure 3. Analysis of marker profiles by discriminant analysis of principal
*components (DAPC). (**A**) DAPC scatter plots show the separation of groups based*
*on discriminant functions 1-3. (**B**) Proteins associated with separation (loading plots)*
for each discriminant function. Loading cut-off set to 0.03.

Selection of proteins indicating different etiologies
To further assess if we could identify an inflammatory signature associated with
each type of infection, we used the Boruta feature selection algorithm to identify

proteins that contributed significant information for the accurate classification of each
disease (**Figure 4**). Since there were only six bacterial respiratory tract infections in
the dataset, we did not try to identify a specific signature for this group, although the
samples were retained in the dataset when classifying the other groups. For the four
remaining diseases, the algorithm identified different numbers of cytokines as
providing significant information for classification, indicated by the green color
(**Figure 4**). We identified 19, 17, 15, and 21 cytokines for dengue, bacterial
gastroenteritis, influenza, and malaria, respectively **(Figure 4).** Several cytokines
were selected as important for the classification of more than one pathogen
(**Supplementary Figure 7**), such as IL10, MIG, sCD25, and sTNFRI which were
selected for all four diseases (**Supplementary Figure 7**).
328

330 **Figure 4. Selecting signatures for detecting individuals infected by each**
331 **pathogen using the Boruta feature selection algorithm.** *(A-D) Variable*
332 *importance plots from the Boruta feature selection algorithm fitted jointly to data for*

all proteins in detecting dengue, bacterial gastroenteritis, influenza, and P. falciparum malaria, respectively. Proteins are ordered from left to right by their importance for classification. The importance measure is defined as the Z-score of the mean decrease in accuracy (normalized permutation importance). Blue boxes correspond to the minimal, average, and maximum Z-scores of shadow features. Red boxes indicate variables not contributing significantly to accurate classification. Green boxes indicate the proteins contributing significantly to the accurate identification of each infection type.

Performance analysis of the classification of different disease etiologies

Following the Boruta feature selection algorithm, binary random forest classifiers were fitted separately to the data for the proteins selected for each infection (from all individuals) in order to evaluate whether they were informative in identifying individuals with a specific infection type. The best cross-validated classifier performance, as determined by the aggregated classifier area-under-curve (AUC), was observed for malaria, followed by bacterial gastroenteritis, influenza, and then dengue (**Figure 5A**). In malaria, we observed an aggregated cross-validated AUC of 0.97 for a combination of 21 cytokines, while for bacterial gastroenteritis, an aggregated AUC of 0.94 was seen for a set of 15 cytokines. For influenza and dengue, aggregated AUCs of 0.91 and 0.90 were observed from combinations of 17 and 19 proteins, respectively. Overall, all classifiers showed good performance (sensitivity > 0.87 and specificity > 0.72) for detecting each particular infection type using the selected signature.

In our binary classification problem, the goal was to distinguish a specific infection (i.e. the case class) from the other infections and healthy controls (i.e. the control class). In each case, the number of individuals in the control class was greater than the case class, resulting in an imbalanced dataset. To address this issue and report a more accurate model performance, we calculated precision-recall curves (**Figure 5B**). In malaria, the dataset imbalance was very low, resulting in a low bias and a good model performance in terms of both AUC and area under the precision-recall curve (AUPR) (with a sensitivity and precision of 0.9). However, for bacterial gastroenteritis and influenza, with a moderate dataset imbalance, the highest sensitivity and precision were 0.8 and 0.7, respectively. For dengue, we observe the lowest sensitivity and precision, of approximately 0.6, mainly due to a larger class imbalance in the data set (**Figure 5B**).

Figure 5. Evaluating performance in identifying individuals infected by each
pathogen based on a combination of protein responses*. Individual panels display*
*(**A***) cross-validated receiver operating characteristic (ROC) curves and (**B***)*
aggregated precision-recall (PR) curves for the identification of dengue (red),
bacterial gastroenteritis (blue), influenza (purple), and malaria (orange). Random
forest classifiers fitted to data on selected proteins that were identified using feature
selection for each pathogen. Gray curves in (A) correspond to the ROC curves
obtained from the 5-fold cross-validation method and the aggregation of all five ROC
curves for the classification of each pathogen is shown with a colored thick ROC
curve. The area under the ROC/PR curve (AUC) shows the performance of the
classifier. An AUROC/AUPR of 0.5 indicates a classifier that performs no better than
random, and an AUROC/AUPR of 1 indicates a perfect classifier.

Discussion

Fever is one of the most common symptoms in patients presenting in an emergency setting, especially following travel to tropical- and subtropical regions[29]. However, fever is a non-specific symptom associated with many different infections, some potentially dangerous[6]. Despite this, a large proportion of patients are discharged without identification of the etiological agent[2]. This could be due to the lack of awareness and/or specific tests for rare pathogens, or difficulty in selecting the accurate test to perform.

Cytokines are immune mediators temporarily produced at high levels during infection, where they provide important functions, such as directly inhibiting pathogen dissemination, stimulating or dampening immune activation, and controlling cellular migration, among other functions[30]. The response is generated as a reaction to pathogen-specific patterns and via antigen-specific recognition, potentially making it specific for a given pathogen[31,32]. This makes it possible to better understand how the immune system responds to a given infection and potentially predict the type of pathogen based on the inflammatory markers that are increased during the infection. With a broad approach of including viral, parasitic, and bacterial infections in febrile patients we show that many cytokines are up- or downregulated compared to healthy controls and further differ between the infections, making us able to identify disease-specific inflammatory profiles.

Using Boruta feature selection, four proteins (IL10, MIG, sCD25, and sTNFRI) were identified to contribute significantly to stratifying between the four infections included in the analysis, indicating a varied expression in different diseases. IL10 was among the top three features selected for patients with *P. falciparum* malaria where IL10 was markedly upregulated (also to some extent in dengue virus infection) and for patients with enteric bacterial infection where it remained at baseline levels similar to healthy controls. The increased level of IL10 in patients with malaria is in line with several previous reports[33–35]. However, by comparing malaria with other infections in this study, it becomes clear that the levels reached during acute *P. falciparum* malaria are very high and appear to be a relatively specific hallmark of the disease. In addition to IL10, patients with *P. falciparum* malaria also had especially high levels of sCD25 and sTNFRI. Both these proteins are soluble receptors with sCD25 corresponding to the IL2 receptor and sTNFRI corresponding to the soluble tumor

necrosis factor receptor 1 or CD120a, which binds TNF-α. It has been suggested that

sCD25 is a marker of T cell activation[36] and has been shown to be increased during

different infections, inflammatory diseases, and cancer[37–39]. Its purpose remains

relatively unclear, but it has been suggested to sequester IL2 and thereby inhibit

excessive T cell activation while simultaneously skewing towards the survival of

CD25^{high} regulatory T cells[40]. sTNFRI is expressed by most cells while sTNFRII is

mainly induced in a subset of cells during inflammatory responses. Both receptors

are elevated in blood during malaria and correlate with parasitemia in both

symptomatic and non-symptomatic infections[41,42] and with the clinical stage and

progression of HIV and sepsis[43]. sTNFRI is suggested to bind and deactivate

excessive TNF to reduce overall inflammation[42]. CD40L is another membrane-

derived protein belonging to the tumor necrosis factor superfamily. It can have both

immunostimulatory and immunoinhibitory effects and soluble CD40L has been

associated with the induction of regulatory T cells immunosuppression in HIV and

cancer[44,45]. One of the main sources of both membrane-bound and soluble CD40L is

platelets[46]. In this study, soluble CD40L was somewhat elevated in enteric bacteria

compared to healthy controls, but the main difference was a relatively specific and

significant reduction in plasma during *P. falciparum* malaria. A potential reason for

this strong reduction in soluble CD40L could be thrombocytopenia, as observed in

the current study and previous studies of malaria[47]. Taken together, the high levels of

IL10, sCD25, sTNFRI and II, and low levels of soluble CD40L suggest that there is a

greatly expanded regulatory or immunosuppressive response generated during acute

malaria, perhaps as a counter-effect to the strong immunostimulation coming from

high levels of parasites in the blood[48]. However, consequently, it has also been

proposed that the strong inflammatory and anti-inflammatory response could affect

the long-lived adaptive B- and T-cell compartment and reduce the generation of

protective immunity[49–51]. Although it is difficult to determine the exact effect of this

combined response, it is clear that repeated malaria episodes lead to reduced

activation of innate immune responses[52–54]. This could be an effect of innate

training[55,56] or cellular dysregulation[53,57], but could also be influenced by adaptive

responses affecting innate activation[19,58,59].

MIG, also called CXCL9, was elevated in all groups compared to healthy

controls, potentially working as a general marker of infection. However, the levels

were also different between the infections with enteric bacteria and *P. falciparum*

malaria having significantly higher levels than both viral and bacterial respiratory tract infections. MIG is induced by IFN-γ and mainly mediates lymphocyte recruitment via binding to its receptor CXCR3[60]. MIG is often also co-expressed with IP10 (also called CXCL10), which was among the top three features selected for dengue virus infection. Like MIG, IP10 was also elevated in all infections, but more so in the dengue group. Since the IFN-γ levels were not higher in dengue compared with enteric bacteria or *P. falciparum* malaria, the increased IP10 levels could come from induction via direct sensing by pattern-recognition receptors[61]. In support of this, the level of type I IFN (IFNa2) was elevated in dengue virus infection, but not in the other groups.

A universal marker or combination of markers that could differentiate viral from bacterial infections would be highly valuable for clinicians. C-reactive protein (CRP) and/or procalcitonin (PCT) levels are commonly used for this purpose with high levels indicating a bacterial infection[62]. CRP is produced in response to IL6, while PCT is produced in response to both IL6, IL1, and other cytokines. Both have a longer half-life than the cytokines that induce them enabling the detection of immune activation or infection for a longer period of time[62]. However, increased IL6 and IL1β production, and consequently CRP and PCT levels, are also seen in different viral infections[63,64] and non-infectious inflammatory diseases[65–67], making it difficult for CRP and PCT to reach recommended target product profiles with >90% sensitivity and >80% specificity[68,69]. Apart from the risk of missing severe or treatable bacterial infections, the threat from overuse of antibiotics leading to antimicrobial resistance is urgent as well[7]. In the tropical fever context, it has been shown that patients with dengue virus infections are often treated with antibiotics[70,71]. In this study, based on 49 markers, we could not find profiles that could fully separate viral from bacterial infections. However, since profiles unique to several highly important pathogens were identified, these combinations of markers could be further analyzed to improve our understanding of disease-specific immune responses and potentially the identification of disease etiologies.

A strength of our results is that we have focused on patients with fever after travel and a variety of different microbiological etiologies, contrasting with many studies where only one pathogen and fewer cytokines are studied[72–74]. Travelers provide a unique opportunity to study pathogens after a single exposure, in contrast

to studies in areas endemic for the diseases. Furthermore, since our study population
was healthy in general with a median age of 37 years, there is little impact from the
effects of chronic disease or medication, which is often prevalent in patients at the
hospital level of care.
In conclusion, our results show that the mapping of cytokine profiles in febrile
patients can identify biomarker combinations that indicate different etiologies.
Additionally, we identified cytokines that were uniquely high or low between the
infection, indicating different biological functions in the host's response to infection.
Future studies, with larger and more balanced groups with independent training and
testing sets, will be important to narrow down the disease signatures to key proteins
that could be further developed for clinical tests.
495

Acknowledgments

We would like to thank all patients and healthy control individuals who
participated in the study. We would also like to express our gratitude to clinicians,
nurses and medical students for assisting us with study inclusion. This study was
supported by funding from the Magnus Bergvall Foundation (2018-02656), Tore
Nilsson Foundation (2018-00608), Swedish Society of Medicine (SLS-934363), Åke
Wiberg Foundation (M18-0076), the Swedish Heart-Lung Foundation (20220566)
and the Swedish Research Council (2019-01940 and 2021-03706) to CS and grants
from Tornspiran foundation to KS and ALF-grants from Region Stockholm to AF.
Work with JG was supported by grants from the Swedish Heart-Lung Foundation
(20190478), the Swedish Research Council (2019-01034), the Regional Agreement
on Medical Training and Clinical Research between Stockholm County Council, and
the Karolinska Institutet (20180120).

Conflict of interest statement

511 The authors declare that there are no conflicting financial interests.
512

Data availability statement

514 The data will be available upon reasonable request to the corresponding author.
515

Code availability statement

All R code for reproducing the analysis are publicly available online at https://github.com/SundlingLab/TF_Cytokines_Study.

References

Herbinger KH, Alberer M, Berens-Riha N *et al.* Spectrum of imported infectious diseases: A comparative prevalence study of 16,817 German travelers and 977 immigrants from the tropics and subtropics. *American Journal of Tropical Medicine and Hygiene* 2016; **94**: 757–766.

Askling HH, Lesko B, Vene S *et al.* Serologic analysis of returned travelers with fever, Sweden. *Emerg Infect Dis* 2009; **15**: 1805–1808.

Mattar S, Tique V, Miranda J, Montes E, Garzon D. Undifferentiated tropical febrile illness in Cordoba, Colombia: Not everything is dengue. *J Infect Public Health* 2017; **10**: 507–512.

Manock SR, Jacobsen KH, de Bravo NB *et al.* Etiology of acute undifferentiated febrile illness in the Amazon basin of Ecuador. *American Journal of Tropical Medicine and Hygiene* 2009; **81**: 146–151.

Jensenius M, Fournier PE, Vene S *et al.* African Tick Bite Fever in Travelers to Rural Sub-Equatorial Africa. *Clinical Infectious Diseases* 2003; **36**: 1411–1417.

Jensenius M, Han P v., Schlagenhauf P *et al.* Acute and Potentially Life-Threatening Tropical Diseases in Western Travelers—A GeoSentinel Multicenter Study, 1996–2011. *Am J Trop Med Hyg* 2013; **88**: 397–404.

Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf* 2014; **5**: 229.

Verhoef J, Snippe H. Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites. *Principles of Immunopharmacology* 2005; : 105–115.

Qin C, Zhou L, Hu Z *et al.* Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases* 2020; **71**: 762–768.

van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. *Nature Reviews Immunology 2017 17:7* 2017; **17**: 407–420.

Chaplin DD. Overview of the immune response. *Journal of Allergy and Clinical Immunology* 2010; **125**: S3–S23.

del Valle DM, Kim-Schulze S, Huang HH *et al.* An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020; **26**: 1636–1643.

Lucas C, Wong P, Klein J *et al.* Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* 2020; **584**: 463–469.

Bozza FA, Cruz OG, Zagne SM *et al.* Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. *BMC Infect Dis* 2008; **8**: 1–11.

Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. Serum Proteome and Cytokine Analysis in a Longitudinal Cohort of Adults with Primary Dengue Infection Reveals Predictive Markers of DHF. *PLoS Negl Trop Dis* 2012; **6**: e1887.

Jadhav M, Nayak M, Kumar S *et al.* Clinical Proteomics and Cytokine Profiling for Dengue Fever Disease Severity Biomarkers. *OMICS* 2017; **21**: 647–657.

17   Mousavian Z, Folkesson E, Fröberg G *et al.* A protein signature associated with
active tuberculosis identified by plasma profiling and network-based analysis.
iScience 2022; **25**: 105652.
18   Kam Y, Ahmed MY, Amrun SN *et al.* Systematic analysis of disease-specific
immunological signatures in patients with febrile illness from Saudi Arabia. *Clin
Transl Immunology* 2020; **9**. doi:10.1002/cti2.1163.
19   Lautenbach MJ, Yman V, Silva CS *et al.* Systems analysis shows a role of
cytophilic antibodies in shaping innate tolerance to malaria. *Cell Rep* 2022; **39**:
110709.
20   Suhre K, Sarwath H, Engelke R *et al.* Identification of Robust Protein
Associations With COVID-19 Disease Based on Five Clinical Studies. *Front
Immunol* 2022; **12**: 5935.
21   D'Onofrio V, Heylen D, Pusparum M *et al.* A prospective observational cohort
study to identify inflammatory biomarkers for the diagnosis and prognosis of
patients with sepsis. *J Intensive Care* 2022; **10**: 1–13.
22   Garishah FM, Boahen CK, Vadaq N *et al.* Longitudinal proteomic profiling of
the inflammatory response in dengue patients. *PLoS Negl Trop Dis* 2023; **17**:
e0011041.
23   Sundling C, Rönnberg C, Yman V *et al.* B cell profiling in malaria reveals
expansion and remodeling of CD11c+ B cell subsets. *JCI Insight* 2019; **4**:
e126492.
24   Vafa Homann M, Emami SN, Yman V *et al.* Detection of Malaria Parasites After
Treatment in Travelers: A 12-months Longitudinal Study and Statistical
Modelling Analysis. *EBioMedicine* 2017; **25**: 66–72.
25   Yman V, White MT, Asghar M *et al.* Antibody responses to merozoite antigens
after natural Plasmodium falciparum infection: Kinetics and longevity in
absence of re-exposure. *BMC Med* 2019; **17**: 22.
26   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical
Society: Series B (Methodological)* 1995; **57**: 289–300.
27   Jombart T, Devillard S, Balloux F. Discriminant analysis of principal
components: A new method for the analysis of genetically structured
populations. *BMC Genet* 2010; **11**: 94.
28   Kursa MB, Rudnicki WR. Feature selection with the boruta package. *J Stat
Softw* 2010; **36**: 1–13.
29   Leder K, Torresi J, Brownstein JS *et al.* Travel-associated Illness Trends and
Clusters, 2000–2010. *Emerg Infect Dis* 2013; **19**: 1049.
30   Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: a
quantitative appraisal of immune complexity. *Nat Rev Immunol* 2019; **19**: 205–
217.
31   Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity.
Cell 2006; **124**: 783–801.
32   Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. *Cell*
2010; **140**: 805–820.
33   Jagannathan P, Eccles-James I, Bowen K *et al.* IFNγ/IL-10 Co-producing Cells
Dominate the CD4 Response to Malaria in Highly Exposed Children. *PLoS
Pathog* 2014; **10**: e1003864.
34   Boyle MJ, Jagannathan P, Bowen K *et al.* The development of Plasmodium
falciparum-Specific IL10 CD4 T cells and protection from malaria in children in
an area of high malaria transmission. *Front Immunol* 2017; **8**: 1329.

35 Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J. High
levels of circulating IL-10 in human malaria. *Clin Exp Immunol* 1994; **95**: 300–3.
36 Rubin LA, Kurman CC, Fritz ME *et al.* Soluble interleukin 2 receptors are
released from activated human lymphoid cells in vitro. *The Journal of*
Immunology 1985; **135**: 3172–3177.
37 Wimmer T, Mattes R, Stemmler H-J *et al.* sCD25 as an independent adverse
prognostic factor in adult HLH patients: results of a multicenter retrospective
study. *Blood Adv* 2022. doi:10.1182/BLOODADVANCES.2022007953.
38 Xie M, Yunis J, Yao Y *et al.* High levels of soluble CD25 in COVID-19 severity
suggest a divergence between anti-viral and pro-inflammatory T-cell
responses. *Clin Transl Immunology* 2021; **10**: e1251.
39 Cabrera R, Ararat M, Cao M *et al.* Hepatocellular carcinoma
immunopathogenesis: Clinical evidence for global T cell defects and an
immunomodulatory role for soluble CD25 (sCD25). *Dig Dis Sci* 2010; **55**: 484–
495.
40 Nickle RA, DeOca KB, Garcia BL, Mannie MD. Soluble CD25 imposes a low-
zone IL-2 signaling environment that favors competitive outgrowth of antigen-
experienced CD25high regulatory and memory T cells. *Cell Immunol* 2023;
384: 104664.
41 Thévenon AD, Zhou JA, Megnekou R, Ako S, Leke RGF, Taylor DW. Elevated
Levels of Soluble Tumor Necrosis Factor Receptors 1 and 2 Correlate with
Plasmodium falciparum Parasitemia in Pregnant Women: Potential Markers for
Malaria-Associated Inflammation. *J Immunol* 2010; **185**: 7115.
42 Kern P, Hemmer CJ, Gallati H *et al.* Soluble tumor necrosis factor receptors
correlate with parasitemia and disease severity in human malaria. *J Infect Dis*
1992; **166**: 930–934.
43 Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D.
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. *Eur*
J Haematol 1995; **54**: 1–8.
44 Jenabian MA, Patel M, Kema I *et al.* Soluble CD40-ligand (sCD40L, sCD154)
plays an immunosuppressive role via regulatory T cell expansion in HIV
infection. *Clin Exp Immunol* 2014; **178**: 102.
45 Huang J, Jochems C, Talaie T *et al.* Elevated serum soluble CD40 ligand in
cancer patients may play an immunosuppressive role. *Blood* 2012; **120**: 3030–
3038.
46 Cognasse F, Duchez AC, Audoux E *et al.* Platelets as Key Factors in
Inflammation: Focus on CD40L/CD40. *Front Immunol* 2022; **13**: 250.
47 Moulin F, Lesage F, Legros AH *et al.* Thrombocytopenia and Plasmodium
falciparum malaria in children with different exposures. *Arch Dis Child* 2003;
88: 540–541.
48 Popa GL, Popa MI. Recent Advances in Understanding the Inflammatory
Response in Malaria: A Review of the Dual Role of Cytokines. *J Immunol Res*
2021; **2021**. doi:10.1155/2021/7785180.
49 Kumar R, Ng S, Engwerda C. The Role of IL-10 in Malaria: A Double Edged
Sword. *Front Immunol* 2019; **10**: 229.
50 Ly A, Hansen DS. Development of B cell memory in malaria. Front Immunol.
2019; **10**. doi:10.3389/fimmu.2019.00559.
51 Ryg-Cornejo V, Ly A, Hansen DS. Immunological processes underlying the
slow acquisition of humoral immunity to malaria. *Parasitology* 2016; **143**: 199–
207.

52 Portugal S, Moebius J, Skinner J *et al.* Exposure-Dependent Control of
Malaria-Induced Inflammation in Children. *PLoS Pathog* 2014; **10**: e1004079.
53 Jagannathan P, Kim CC, Greenhouse B *et al.* Loss and dysfunction of
Vdelta2(+) gammadelta T cells are associated with clinical tolerance to malaria.
Sci Transl Med 2014; **6**: 251ra117.
54 Jagannathan P, Lutwama F, Boyle MJ *et al.* Vδ2+ T cell response to malaria
correlates with protection from infection but is attenuated with repeated
exposure. *Sci Rep* 2017; **7**: 11487.
55 Guha R, Mathioudaki A, Doumbo S *et al.* Plasmodium falciparum malaria
drives epigenetic reprogramming of human monocytes toward a regulatory
phenotype. *PLoS Pathog* 2021; **17**: e1009430.
56 Nahrendorf W, Ivens A, Spence PJ. Inducible mechanisms of disease
tolerance provide an alternative strategy of acquired immunity to malaria. *Elife*
2021; **10**. doi:10.7554/ELIFE.63838.
57 Dobbs KR, Embury P, Vulule J *et al.* Monocyte dysregulation and systemic
inflammation during pediatric falciparum malaria. *JCI Insight* 2017; **2**.
doi:10.1172/jci.insight.95352.
58 Weiss GE, Traore B, Kayentao K *et al.* The plasmodium falciparum-specific
human memory b cell compartment expands gradually with repeated malaria
infections. *PLoS Pathog* 2010; **6**: 1–13.
59 Crabtree JN, Caffrey DR, Silva L de S *et al.* Lymphocyte crosstalk is required
for monocyte-intrinsic trained immunity to Plasmodium falciparum. *J Clin Invest*
2022; **132**. doi:10.1172/JCI139298.
60 Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of
the mechanisms that may contribute to the non-redundant activities of
interferon-inducible CXC chemokine receptor 3 ligands. *Front Immunol* 2018; **8**:
1970.
61 Elemam NM, Talaat IM, Maghazachi AA. CXCL10 Chemokine: A Critical Player
in RNA and DNA Viral Infections. *Viruses* 2022; **14**. doi:10.3390/V14112445.
62 Zandstra J, Jongerius I, Kuijpers TW. Future Biomarkers for Infection and
Inflammation in Febrile Children. *Front Immunol* 2021; **12**: 1462.
63 Gautam S, Cohen AJ, Stahl Y *et al.* Severe respiratory viral infection induces
procalcitonin in the absence of bacterial pneumonia. *Thorax* 2020; **75**: 974–
981.
64 Russo A, Venditti M, Ceccarelli G, Mastroianni CM, d'Ettorre G. Procalcitonin in
daily clinical practice: an evergreen tool also during a pandemic. *Intern Emerg*
Med 2021; **16**: 541–543.
65 Tian F, Li H, Wang L *et al.* The diagnostic value of serum C-reactive protein,
procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe
acute pancreatitis. *Clin Chim Acta* 2020; **510**: 665–670.
66 Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis
and associated comorbidities. *Semin Arthritis Rheum* 2021; **51**: 219–229.
67 Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of
inflammatory markers for cancer diagnosis in primary care: a prospective
cohort study using electronic health records. *Br J Cancer* 2019; **120**: 1045–
1051.
68 Dittrich S, Tadesse BT, Moussy F *et al.* Target Product Profile for a Diagnostic
Assay to Differentiate between Bacterial and Non-Bacterial Infections and
Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert
Consensus. *PLoS One* 2016; **11**: e0161721.

714 69 Watson J, Salisbury C, Whiting P, Banks J, Pyne Y, Hamilton W. Added value
715   and cascade effects of inflammatory marker tests in UK primary care: a cohort
716   study from the Clinical Practice Research Datalink. *British Journal of General*
717   *Practice* 2019; **69**: e470–e478.
718 70 Adrizain R, Setiabudi D, Chairulfatah A. The inappropriate use of antibiotics in
719   hospitalized dengue virus-infected children with presumed concurrent bacterial
720   infection in teaching and private hospitals in Bandung, Indonesia. *PLoS Negl*
721   *Trop Dis* 2019; **13**: e0007438.
722 71 Denny KJ, Gartside JG, Alcorn K, Cross JW, Maloney S, Keijzers G.
723   Appropriateness of antibiotic prescribing in the Emergency Department.
724   *Journal of Antimicrobial Chemotherapy* 2019; **74**: 515.
725 72 Rathakrishnan A, Wang SM, Hu Y *et al.* Cytokine Expression Profile of Dengue
726   Patients at Different Phases of Illness. *PLoS One* 2012; **7**: e52215.
727 73 He Y, Feng Z, Wang W *et al.* Global cytokine/chemokine profile identifies
728   potential progression prediction indicators in hand-foot-and-mouth disease
729   patients with Enterovirus A71 infections. *Cytokine* 2019; **123**: 154765.
730 74 Barros JB de S, da Silva PAN, Koga R de CR *et al.* Acute Zika virus infection in
731   an endemic area shows modest proinflammatory systemic immunoactivation
732   and cytokine-symptom associations. *Front Immunol* 2018; **9**: 3.
733